Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Lancet Haematol. 2022 May;9(5):e350–e360. doi: 10.1016/S2352-3026(22)00076-X

Figure 2:

Figure 2:

Event-free survival within propensity score matched patients treated with VEN+IC compared to IC(A). Overall survival in patients treated with VEN+IC compared to IC(B). Event-free survival in patients with ELN intermediate or adverse risk AML treated with VEN+IC compared to IC(C). Overall survival in patients with intermediate or adverse risk AML treated with VEN+IC compared to IC (D).